Aishwarya Vijay1, Alexander R Bazazi2, Ilias Yee3, Adeeba Kamarulzaman4, Frederick L Altice5. 1. Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, New Haven, CT 06510, USA. 2. Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, New Haven, CT 06510, USA; Yale University School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, CT, USA. 3. Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia. 4. Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, New Haven, CT 06510, USA; Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia. 5. Yale University School of Medicine, Department of Medicine, Section of Infectious Diseases, AIDS Program, 135 College Street, New Haven, CT 06510, USA; Yale University School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, CT, USA; Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia. Electronic address: Frederick.Altice@Yale.edu.
Abstract
BACKGROUND: Little is known about attitudes toward and experiences with opioid maintenance therapy (OMT) among people who inject drugs in Malaysia, a country where people who inject drugs comprise 1.3% of the adult population. METHODS: In 2010, 460 people who inject drugs in Greater Kuala Lumpur, Malaysia were surveyed to evaluate attitudes toward and experiences with OMT and treatment readiness. Attitudes towards OMT with both methadone and buprenorphine were assessed using an opinions scale. Multivariable linear regression was used to assess correlates of treatment readiness, measured with the 19-item Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). RESULTS: All 460 participants used opioids and nearly all (99.1%) met criteria for opioid dependence. Few had had previous experience with methadone (9.3%) or buprenorphine (12.6%) maintenance therapy, yet many had used methadone (55.2%) or buprenorphine (51.7%) outside of treatment settings. Fifteen percent had injected buprenorphine in the past month, and of the few that were currently receiving buprenorphine maintenance therapy, almost all were injecting it. The majority of subjects exhibited a moderate level of treatment readiness and a preference for methadone over buprenorphine. Those with low treatment readiness scores were more likely to have previous experience with compulsory drug detention centers (p<0.01), needle/syringe exchange programs (p<0.005), or be of Indian ethnicity (p<0.001). Past use of methadone (p<0.01), older age (p<0.001), higher stress symptom severity (p<0.001), and sharing of needles or syringes (p<0.05) were associated with higher treatment readiness scores. CONCLUSION: There are suboptimal levels of OMT experience among people who inject drugs that may be improved by addressing factors that influence patient attitudes. Those individuals with moderate treatment readiness may be targeted by brief motivational and cognitive interventions in primary care, prisons or OMT clinics aimed at improving entry into and retention in treatment.
BACKGROUND: Little is known about attitudes toward and experiences with opioid maintenance therapy (OMT) among people who inject drugs in Malaysia, a country where people who inject drugs comprise 1.3% of the adult population. METHODS: In 2010, 460 people who inject drugs in Greater Kuala Lumpur, Malaysia were surveyed to evaluate attitudes toward and experiences with OMT and treatment readiness. Attitudes towards OMT with both methadone and buprenorphine were assessed using an opinions scale. Multivariable linear regression was used to assess correlates of treatment readiness, measured with the 19-item Stages of Change Readiness and Treatment Eagerness Scale (SOCRATES). RESULTS: All 460 participants used opioids and nearly all (99.1%) met criteria for opioid dependence. Few had had previous experience with methadone (9.3%) or buprenorphine (12.6%) maintenance therapy, yet many had used methadone (55.2%) or buprenorphine (51.7%) outside of treatment settings. Fifteen percent had injected buprenorphine in the past month, and of the few that were currently receiving buprenorphine maintenance therapy, almost all were injecting it. The majority of subjects exhibited a moderate level of treatment readiness and a preference for methadone over buprenorphine. Those with low treatment readiness scores were more likely to have previous experience with compulsory drug detention centers (p<0.01), needle/syringe exchange programs (p<0.005), or be of Indian ethnicity (p<0.001). Past use of methadone (p<0.01), older age (p<0.001), higher stress symptom severity (p<0.001), and sharing of needles or syringes (p<0.05) were associated with higher treatment readiness scores. CONCLUSION: There are suboptimal levels of OMT experience among people who inject drugs that may be improved by addressing factors that influence patient attitudes. Those individuals with moderate treatment readiness may be targeted by brief motivational and cognitive interventions in primary care, prisons or OMT clinics aimed at improving entry into and retention in treatment.
Authors: Steffanie A Strathdee; Erin P Ricketts; Steven Huettner; Lee Cornelius; David Bishai; Jennifer R Havens; Peter Beilenson; Charles Rapp; Jacqueline J Lloyd; Carl A Latkin Journal: Drug Alcohol Depend Date: 2005-12-20 Impact factor: 4.492
Authors: Louisa Degenhardt; Bradley M Mathers; Andrea L Wirtz; Daniel Wolfe; Adeeba Kamarulzaman; M Patrizia Carrieri; Steffanie A Strathdee; Kasia Malinowska-Sempruch; Michel Kazatchkine; Chris Beyrer Journal: Int J Drug Policy Date: 2013-09-04
Authors: Alexander R Bazazi; Forrest Crawford; Alexei Zelenev; Robert Heimer; Adeeba Kamarulzaman; Frederick L Altice Journal: AIDS Behav Date: 2015-12
Authors: Alexander R Bazazi; Aishwarya Vijay; Forrest W Crawford; Robert Heimer; Adeeba Kamarulzaman; Frederick L Altice Journal: AIDS Care Date: 2017-08-13
Authors: Trena I Mukherjee; Jeffrey A Wickersham; Mayur M Desai; Veena Pillai; Adeeba Kamarulzaman; Frederick L Altice Journal: Drug Alcohol Depend Date: 2016-05-09 Impact factor: 4.492
Authors: Jeffrey A Wickersham; Kelsey B Loeliger; Ruthanne Marcus; Veena Pillai; Adeeba Kamarulzaman; Frederick L Altice Journal: Am J Drug Alcohol Abuse Date: 2015-12-04 Impact factor: 3.829
Authors: Gabriel J Culbert; Veena Pillai; Joseph Bick; Haider A Al-Darraji; Jeffrey A Wickersham; Martin P Wegman; Alexander R Bazazi; Enrico Ferro; Michael Copenhaver; Adeeba Kamarulzaman; Frederick L Altice Journal: J Neuroimmune Pharmacol Date: 2016-05-24 Impact factor: 4.147
Authors: Enrico G Ferro; Gabriel J Culbert; Jeffrey A Wickersham; Ruthanne Marcus; Alana D Steffen; Heather A Pauls; Ryan P Westergaard; Christopher K Lee; Adeeba Kamarulzaman; Frederick L Altice Journal: Open Forum Infect Dis Date: 2017-01-25 Impact factor: 3.835